EDMONTON, Feb. 15 /CNW/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has secured long-term manufacturing agreements with two global companies, UCB-Bioproducts and Hospira Worldwide Inc., for its lead MS drug MBP8298.
